**In vitro** Anti-inflammatory Effects of *Satureja Khuzestanica* Essential Oil Compared to Carvacrol

Masumeh Jalalvand1, Gholamreza Shahsavari2, Ali Sheikhan3, Ali Ganji4, Ghasem Mosayebi5

1Molecular and Medicine Research Center, Arak University of Medical Sciences, Arak, Iran
2Department of Biochemistry, School of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran
3Department of Immunology, School of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran
4Department of Microbiology and Immunology, School of Medicine, Arak University of Medical Sciences, Arak, Iran
5*Correspondence to Ghasem Mosayebi, Tel: +98 86 34173502 ghasemmosayebi@arakmu.ac.ir

**Abstract**

**Introduction:** *Satureja khuzestanica* grows mainly in the southwest part of Iran as a native plant. This edible herb contains various compounds including the *S. khuzestanica* essential oil (SKEO) and monoterpene known as Carvacrol. Previous studies have shown the anti-inflammatory effects of *S. Khuzestanica* without mentioning the exact mechanism of its function. Given that prostaglandin synthesis, which is one of the main mediators of inflammation, is regulated by the cyclooxygenase-2 (COX2) gene, the present study investigated the effects of SKEO and Carvacrol on the expression of the COX2 gene in the stimulated-J774A.1 macrophage cell line.

**Methods:** To this end, fresh aerial parts of the plant were processed to prepare SKEO. Then, different doses of SKEO and Carvacrol (i.e., 0.004%, 0.008%, and 0.016% v/v) were used to treat with the lipopolysaccharides (LPS)-stimulated cell line for eight hours. After RNA extraction, the real-time polymerase chain reaction technique was applied for gene expression analysis.

**Results:** In the LPS-stimulated J774A.1 macrophage cell line, COX2 gene expression reduced significantly in a dose-dependent manner (0.004%, 0.008%, and 0.016%, P = 0.024, P = 0.021, and P = 0.013 v/v of SKEO, respectively) by SKEO, and the effect of Carvacrol was less powerful (0.008% and 0.016%, P = 0.027 and P = 0.038 v/v, respectively) compared to SKEO. Finally, the comparison between SKEO and Carvacrol showed higher significant inhibitory effects of SKEO on COX2 gene expression in comparison with Carvacrol in 0.004% v/v concentration (P = 0.037).

**Conclusion:** In general, SKEO significantly reduced COX2 gene expression, thus it can be suggested that its anti-inflammatory effect may result from the inhibition of the synthesis of this pro-inflammatory gene.

**Keywords:** Carvacrol, *Satureja khuzestanica*, Cyclooxygenase-2 gene

**Introduction**

*Satureja khuzestanica* (*S. Khuzestanica*), as an herbaceous and aromatic medicinal plant, grows in the southwest part (i.e., Lorestan and Khuzestan provinces) of Iran. It was first identified and named by Jamzad in 1994.1 Recently, different studies have proven the anti-inflammatory and anti-analgesic effects of *S. Khuzestanica*.2

*S. khuzestanica* contains the *S. Khuzestanica* essential oil (SKEO). The gas chromatography-mass spectrometry analysis of SKEO shows that flavonoids include Carvacrol (2-methyl-5-isopropyl phenol, 86.29%) and Paracemin (3.35%) as their main components.3 Carvacrol is a monoterpene compound with anti-inflammatory properties.4 Many mediators such as prostaglandins can modulate inflammatory processes. One of the key enzymes, which is involved in prostaglandin synthesis, is cyclooxygenase (COX) that has three isoforms of COX1, COX2, and COX3.5 COX2 is rapidly expressed by extracellular stimuli as part of the inflammatory reaction and is undetectable in many normal tissues. In addition, it is actually associated with inflammation situations like pain, fever, and atherosclerosis through prostaglandin synthesis.6

The long-term consumption of COX2 suppressors such as nonsteroidal anti-inflammatory drugs (NSAIDs) can boost the risk of cardiovascular diseases with side...
effects in the digestive system and kidneys.\textsuperscript{7,8} Therefore, medicinal plants with fewer side effects could play critical roles in treating inflammation. Hence, the present study evaluated the effect of SKEO on COX2 gene expression, as one of the enzymes involved in inflammation regulation.

**Materials and Methods**

**SKEO Preparation**

*S. Khuzestanica*, which was grown in Khorramabad (Lorestan province in the west of Iran), identified by Medicinal Herbs Research Center of National Forestry Organization, and finally used for SKEO preparation based on previous protocols.\textsuperscript{9,10} Carvacrol was also purchased from Sigma Company (Sigma, MO, USA).

**Macrophage Cell Line Treatment**

The J774A.1 murine macrophage cell line was purchased from the Pasteur Institute of Iran (Code No; NCBI-C483). The cells were cultured in the RPMI-1640 medium (Gibco, NY, USA) supplemented with a 10% fetal bovine serum (Gibco, NY, USA), 100 µg/mL streptomycin (Sigma, MO, USA), and 100 µg/mL penicillin (Sigma, MO, USA) under 5% CO\textsubscript{2} and 95% humidity at 37 °C. The cultured cells at the density of 5x10\textsuperscript{5} cells/well were stimulated with 1 µg/mL of lipopolysaccharides (LPS, Sigma, MO, USA) according to the manufacturer's instructions. Then, the synthesized cDNA was amplified in duplicates using the LightCycler FastStart DNA Master SYBR Green I kit (Roche Diagnostics, Mannheim, Germany) based on previous protocols.

The extracted RNA was reverse-transcribed into cDNA (Applied Biosystems, CA, USA) according to the manufacturer's instructions. The total RNA was extracted from harvested cells using the Promega RNA extraction kit (Promega, Madison, WI, USA) supplemented with a 10% fetal bovine serum (Gibco, NY, USA) and 100 µg/mL streptomycin (Sigma, MO, USA) under 5% CO\textsubscript{2} and 95% humidity at 37 °C. The cultured cells at the density of 5x10\textsuperscript{5} cells/well were stimulated with 1 µg/mL of lipopolysaccharides (LPS, Sigma, MO, USA) in parallel with the control (without LPS stimulation). Both LPS-stimulated and non-stimulated samples were treated with different concentrations of Carvacrol and SKEO (i.e., 0.00%, 0.004%, 0.008%, and 0.016% v/v) in separate wells for eight hours to be used in the evaluation of COX2 gene expression.

**Gene Expression Analysis**

The total RNA was extracted from harvested cells using the Promega RNA extraction kit (Promega, Madison, USA) according to the manufacturer's instructions. The extracted RNA was reverse-transcribed into cDNA (Fermentas, USA) according to the manufacturer's instructions. Then, the synthesized cDNA was amplified in duplicates using the LightCycler FastStart DNA Master SYBR Green I kit (Roche Diagnostics, Mannheim, Germany) by the real-time polymerase chain reaction (Applied Biosystems, CA, USA). In addition, the forward and reverse primers (Table 1) of COX2 (accession number: NM_011198) and beta-actin (Actb; accession number: NM_007393) as target and housekeeping genes were designed, respectively, using Allele ID software (version 7.5, Premier Biosoft, CA, USA) and confirmed by PubMed/Blast. Finally, the data were analyzed by the 2^{-ΔΔCT} method.

**Statistical analysis**

SPSS software version 16.0 (SPSS, Inc., Chicago, Illinois, USA) was used for statistical analysis. Independent sample t-test was used to explore meaningful differences between variables in each group. Mann–Whitney U test was used for comparisons the results between the studied groups. P value < 0.05 was considered as statistically significant.

**Results**

**Carvacrol effect on COX2 gene expression**

The Carvacrol effect on the expression of COX2 in the J774A.1 cell line was measured in the absence and presence of LPS. The effects of different doses (0.00%, 0.004%, 0.008%, and 0.016% v/v) of Carvacrol on control and test samples are shown in Figure 1. LPS induced COX2 gene expression in all treated samples, but Carvacrol inhibits significantly gene expression dose-dependently (0.008%; \( P=0.027 \) and 0.016%; \( P=0.038 \) v/v) in LPS–treated test sample (Figure 1).

**SKEO Effect on COX2 Gene Expression**

The SKEO effect on COX2 gene expression in the J774A.1 cell line was measured in the absence and presence of LPS. The samples were treated by different doses of SKEO (i.e., 0.00%, 0.004%, 0.008%, and 0.016% v/v) to verify the effect of this compound on COX2 gene expression. As shown in Figure 2, the COX2 gene expression reduced significantly (0.004%, 0.008%, and 0.016% v/v) to verify the effect of this compound on COX2 gene expression. As shown in Figure 2, the COX2 gene expression reduced significantly (0.004%, 0.008%, and 0.016% v/v) to verify the effect of this compound on COX2 gene expression. As shown in Figure 2, the COX2 gene expression reduced significantly (0.004%, 0.008%, and 0.016% v/v) to verify the effect of this compound on COX2 gene expression. As shown in Figure 2, the COX2 gene expression reduced significantly (0.004%, 0.008%, and 0.016% v/v) to verify the effect of this compound on COX2 gene expression. As shown in Figure 2, the COX2 gene expression reduced significantly (0.004%, 0.008%, and 0.016% v/v) to verify the effect of this compound on COX2 gene expression. As shown in Figure 2, the COX2 gene expression reduced significantly (0.004%, 0.008%, and 0.016%, \( P=0.024, P=0.021, P=0.013 \) v/v of SKEO, respectively) in LPS-stimulated cells.

**Comparison of the Effect of Carvacrol and SKEO on COX2 Gene Expression**

Carvacrol and SKEO inhibited the expression of COX2 gene expression in the LPS-induced J774A.1 macrophage cell line. Figure 3 shows higher significant inhibitory effects of SKEO on COX2 gene expression compared to Carvacrol in 0.004% v/v concentration (\( P=0.037 \)).

**Discussion**

Inflammation, as a central constituent of many pathological conditions, has serious consequences for patients with a chronic form of inflammation and is considered as one of the important factors of tumor development.\textsuperscript{11} In this regard, inflammatory mediators may play some roles in CNS disorders such as Alzheimer’s, autoimmune-like rheumatoid arthritis, and cardiovascular diseases.\textsuperscript{12-14}

Some mediators of inflammation are derived from the endogenous substances of the body like the arachidonic acid which is a normal constituent of cellular membranes.\textsuperscript{15}

### Table 1. Sequences of the Designed Primers

| Name      | Accession Number | Primers 5′→3′             | Amplicon Length (bp) |
|-----------|-----------------|---------------------------|----------------------|
| β-actin   | NM_007393       | F: AGCTTCTTTGCAGCTCCTTC R: GCTTTGGAACATGCGGA | 107                  |
| COX2      | NM_011198       | F: TGGCACTATGGTTACAAAAGCTGG R: TCAGGAAAGCTCCTATTTCCCTT | 124                  |

*Note: COX2: Cyclooxygenase-2; F: Forward; R: Reverse.*
Arachidonic acid is a fatty acid that is a precursor of prostaglandins which are one of the important mediators of inflammation. Furthermore, the conversion of this precursor to prostaglandins is catalyzed by a key enzyme called COX2. Moreover, the lipopolysaccharide of Gram-negative bacteria and some interleukins induce prostaglandin production which could be suppressed by the inhibition of COX2 and inducible nitric oxide (iNOS) synthesis. Previous research has confirmed the beneficial effect of iNOS and COX2 inhibition.

COX2 activity has been studied in many diseases including Parkinson’s disease in which the pathogenesis role of COX2 is noticeable. The result of a study showed that there is an association between COX2 activity and disease progression since COX2 suppression led to disease amelioration. Based on the findings of another study, the suppression of COX2 activity by nonsteroidal anti-inflammatory drugs (NSAIDs) was associated with a reduction in intestine cancer incidence in human and animal models. Additionally, the inhibition of COX2 enzyme production was associated with anti-inflammatory effects. However, the long-term consumption of selective COX2 inhibitory compounds such as NSAIDs has unwanted effects on cardiovascular, gut, and renal systems. Accordingly, more studies should be conducted on the treatment of inflammation in elderly patients in order to develop a better substituent for NSAIDs because of their dangerous side effects.

To this end, the current study investigated the effect of two natural products of Carvacrol and SKEO on COX2 gene expression in the J774A.1 macrophage cell line. Based on the results, both of these compounds reduced COX2 gene expression dose-dependently in the absence and presence of LPS. Similarly, the inhibitory effect of SKEO was more potent than Carvacrol which is the main constituent of the S. Khuzestanica herb. This enhanced inhibitory effect could be due to other components of the herb other than Carvacrol. Amanlou et al showed that S. Khuzestanica has anti-inflammatory effects They also investigated the anti-inflammatory effects of S. Khuzestanica in comparison with indomethacin and concluded that it is as potent as this standard drug. In a similar study, Ghazanfari et al found that the anti-inflammatory effects of the plant were comparable with prednisolone. Other properties of S. Khuzestanica, along with its anti-
inflammatory activity have also received attention. One of these studies evaluated the antioxidant activity of the plant and reported that *S. Khuzestanica* can inhibit the oxidation of low-density lipoprotein (LDL) by copper sulfate in a dose-dependent manner (50-200 μg/mL). The research further claimed that *S. Khuzestanica* could be a good candidate for reducing the risk of cardiovascular and atherosclerotic disease development.

Another previous research evaluated the effect of *S. Khuzestanica* on lipid profile, atherogenic indices, alanine aminotransferase, aspartate aminotransferase (AST), and alkaline phosphatase. It was shown that *S. Khuzestanica* can reduce the level of fasting blood sugar, triglyceride, LDL, and high-density lipoprotein in diabetic mice. The level of hepatic enzymes except for AST also reduced by the extract of *S. Khuzestanica*. Thus, the consumption of this plant may reduce the risk of atherosclerosis and hepatic disease in diabetic patients.

Eventually, Ahmadvand et al studied the effect of *S. Khuzestanica* on lipid peroxidation in diabetic mice in vivo and in-vitro studies. To this end, they removed the livers and kidneys of diabetic mice just after treatment with the *S. Khuzestanica* extract and measured lipid peroxidation by the thiobarbituric acid method. It was observed that could remarkably *S. Khuzestanica* reduce LDL oxidation in-vitro. The findings also revealed that *S. Khuzestanica* reduced lipid peroxidation, glomerular hypertrophy, and glomerulosclerosis in diabetic mice. Therefore, a protective role against peroxidation may prevent the adverse effects of diabetes, including nephropathy in diabetic patients.

**Conclusion**

In summary, the result of this study showed that SKEO and its main component, namely, Carvacrol can inhibit COX2 gene expression thus and *S. Khuzestanica* may be useful in the treatment of inflammatory diseases.

**Ethical Approval**

The study protocol was approved by the Ethics Committee of Arak University of Medical Sciences, Arak, Iran (Code No: 90-119-6).

**Conflict of Interest Disclosure**

The authors declare no competing interests.

**Authors’ Contributions**

Masumeh Jalalvand, Ali Sheikhan, and Gholamreza Shahsavari extracted the Satureja oil and performed all experiments. In addition, Ali Ganji analysed the results and then wrote and revised the paper. Finally, Ghasem Mosayebi designed and supervised the project.

**Acknowledgements**

This work was supported by a grant from the Molecular and Medicine Research Center, Arak University of Medical Sciences. We thank all the members of the research committee.

**References**

1. Jamzad Z. A new species of the genus Satureja (Labiatae) from Iran. Iranian J. Bot. 1994;6(2):215-218.
2. Amanlou M, Dadkhah F, Salehinia A, Farsam H, Dehpour AR. An anti-inflammatory and anti-nociceptive effects of hydroalcoholic extract of Satureja khuzistanica Jamzad extract. J Pharm Pharm Sci. 2005;8(1):102-106.
3. Farsam H, Amanlou M, Radpour M, Salehinia A. Composition of the essential oils of wild and cultivated Satureja khuzistanica Jamzad from Iran. FLAVOUR FRAG J. 2004;19(4):308-310. doi:10.1002/fjfi.1300
4. Baser KH. Biological and pharmacological activities of carvacrol and carvacrol bearing essential oils. Curr Pharm Des. 2008;14(29):3106-3119. doi:10.2174/138161208786404227
5. Vecchio AJ, Simmons DM, Malkowski MG. Structural basis of fatty acid substrate binding to cyclooxygenase-2. J BIOL CHEM. 285(29):22152-22163. doi:10.1074/jbc.M110.119867
6. Cipollone F, Fazia ML, COX-2 and atherosclerosis. J CARDOVASC PHARM T. 2006;47:S26-S36. doi:10.1097/0005344-200605001-00006
7. Harirforoosh S, Jamali FE. Renal adverse effects of nonsteroidal anti-inflammatory drugs. Expert opinion on drug safety. 2009;8(6):669-681. doi:10.1517/14740330903311023
8. Thieffin G, Beaugerie L. Toxic effects of nonsteroidal antiinflammatory drugs on the small bowel, colon, and rectum. Joint Bone Spine. 2005;72(4):286-294. doi:10.1016/j.jbspin.2004.10.004
9. Jalalvand M, Shahsavari G, Mosayebi G. The Inhibitory Effect of Satureja khozestanica Essential Oil and Carvacrol on Nitric Oxide Production in Macrophage Cell Line. ZAHEDAN J RES MED SCI. 2014;16(3):31-34.
10. Khorramabad I, Satureja Khuzestanica essential oil (SKEO) inhibits iNOS gene expression in Lipopolysaccharide-stimulated J774A. 1 macrophage cell line. Life Sci J. 2013;10(2s).
11. Terzic J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology.138(6):2101-2114. e2105. doi:10.1053/j.gastro.2010.01.058
12. Lucas S-M, Rothwell NJ, Gibson RM. The role of inflammation in CNS injury and disease. Br. J. Pharmacol. 2006;147(S1):S232-S240. doi: 10.1038/sj.bjp.0706400
13. Anderson GD, Hauser SD, McGregor KL, Bremer ME, Isakson PC, Gregory SA. Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. J Clin Invest. 1996;97(11):2672. doi:10.1172/JCI118717
14. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation. 2004;109(21 suppl 1):II-2. doi:10.1161/01.CIR.0000129535.04194.38
15. Claria J. Cyclooxygenase-2 biology. Curr Pharm Des. 2003;9(27):2177-2190. doi:10.2174/1381612035454054
16. Simmons DL, Rotting RM, Hla T. Cyclooxygenase-2: the biology of prostaglandin synthesis and inhibition. Pharmaco. Rev. 2004;56(3):387-437. doi:10.1124/pr.56.3.3
17. Sook Chi Y, Sun Cheon B, Pyo Kim H. Effect of wogonin, a plant flavone from Scutellaria radix, on the suppression of cyclooxygenase-2 and the induction of inducible nitric oxide synthase in lipopolysaccharide-treated RAW 264.7 cells. Biochem. Pharmacol. 2001;61(10):1195-1203. doi:10.1016/S0006-2952(01)00597-4

18. Teismann P, Vila M. COX2 and Neurodegeneration in Parkinson’s Disease. ANN NY ACAD SCI. 2003;991(1):272-277. doi:10.1111/j.1749-6632.2003.tb07482.x

19. Ferrandez A, Prescott S, Burt R. COX-2 and colorectal cancer. Curr Pharm Des. 2003;9(27):2229-2251. doi:10.2174/1381612033454036

20. Kuo C-L, Chi C-W, Liu T-Y. The anti-inflammatory potential of berberine in vitro and in vivo. Cancer letters. 2004;203(2):127-137. doi:10.1016/j.canlet.2003.09.002

21. Lanas A, Perez-Aisa MA, Feu F, Ponce J, Sapers E, Santolario S, et al. A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use. AM J GASTROENTEROL. 2005;100(8):1685-1693. doi:10.1111/j.1572-0241.2005.41833.x

22. Ghazanfari G, Minaie B, Yasa N, Nakhai LA, Mohammadirad A, Nikfar S, et al. Biochemical and histopathological evidences for beneficial effects of Satureja khuzestanica jamzad essential oil on the mouse model of inflammatory bowel diseases. TOXICOL MECH METHOD. 2006;16(7):365-372. doi:10.1080/15376520600620125

23. Bagheri S, Ahmadvand H, Khosrowbeygi A, Ghazanfari F, Jafari N, Nazem H, et al. Antioxidant properties and inhibitory effects of Satureja khuzestanica essential oil on LDL oxidation inducedâ€²CuSO 4 in vitro. Asian Pac. J. Trop. Biomed.;3(1):22-27. doi:10.1016/S2221-1691

24. Ahmadvand H, Tavafi M, Khalatbary AR. Hepatoprotective and Hypolipidemic Effects of Satureja Khuzestanica Essential Oil in Alloxan-induced Type I Diabetic Rats. Iran J Pharm Res. 2012;11(4):1219-1226.

25. Ahmadvand H, Tavafi M, Khorshiebeygi A, Shalshavari G, Hormozi M, Beyranvand K, et al. Amelioration of lipid peroxidation in vivo and in vitro by Satureja khuzestanica essential oil in alloxan-induced diabetic rats. J Diabetes Metab Disord. 2014;13(1):119. doi:10.1186/s40200-014-0119-9